ProSTAR: CPI-1205 in Metastatic Castration Resistant Prostate Cancer
Español  |  中國傳統的  |  简体中文
Call us  (855) 528-7322
Main Menu

ProSTAR: CPI-1205 in Metastatic Castration Resistant Prostate Cancer

Sponsor: Constellation Pharmaceuticals, Inc.

ProSTAR: A trial of CPI-1205 plus cobicistat and enzalutamide or abiraterone in metastatic, castration resistant, prostate cancer who have previously received treatment with at least one prior line of a second generation androgen inhibitor.